| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015288 |
| Receipt No. | R000017782 |
| Scientific Title | Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease |
| Date of disclosure of the study information | 2014/09/30 |
| Last modified on | 2019/04/03 (Ver. 8) |
| Basic information | ||
| Public title | Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease | |
| Acronym | Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease | |
| Scientific Title | Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease | |
| Scientific Title:Acronym | Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease | |
| Region |
|
|
| Condition | ||
| Condition | COPD | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of this study is to investigate the efficacy of morphine for dyspnea in patients with COPD. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Dyspnea NRS change between before (Day 0 evening) and after morphine treatment (Day 2 evening) |
| Key secondary outcomes | 1. Dyspnea NRS change between before (Day 0 morning) and after morphine treatment (Day 1 morning, Day 2 morning)
2. Dyspnea NRS change between before (Day 0 evening) and after morphine treatment (Day1 evening). 3. Respiratory rate, blood puressure, SpO2 4. Sleep disturbance 5. Nausea NRS, Somnolence NRS, Anorexia NRS, 6. Nausea and constipation grade in CTCAE v4.0 7. Sedation 8. Derilium 9. Other adverse effect 10. Spontaneous bowel movement |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral morphine 3mg or 2mg every 6 hours (total six times) | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Hospitalized patients with diagnosis of COPD based on the criteria of GOLD 2014 (FEV1/FVC<70%)
2. Patients with severe dyspnea at rest after standard treatment for dypnea 3. Patients aged 40 years-old or older at the time of obtaining informed consent 4. Patients with history of cigarette smoking of at least 10 pack-years 5. Patients who have the following data at baseline: AST <= 100 IU/L ALT <= 100 IU/L T-BIL <= 2.0 mg/dL eGFR >= 30 mL/min SPO2 >= 90 % (Oxygen is allowed) PaCO2 <= 60 Torr (Oxygen is allowed) 6. Patients who receive enough other treatment fo dyspnea of COPD 7. Patients with expected survival of 1 month or longer 8. Patients with lucidity and capability of communication and without cognitive inpairments 9. Patients who agree to participate the study with written informed consent |
|||
| Key exclusion criteria | 1. Patients with contraindication of morphine (ex. allergy for morphine and history of severe adverse effects of morphine)
2. Patients who use opioid. Patients who did not use codein within 3 days before study entry are eligble. 3. Patients with COPD acute exacerbation 4. Patients with active infection that causes dyspnea 5. Patients with lung cancer that causes dyspnea 6. Patients with pneumothorax 7. Patients who uses invasive positive airway pressure ventilation. Patients who uses nasal high flow were not excluded 8. Patients who changed the way of intaking of bronchodilators, corticosteroids, vasodilators and anxiolytics within two days before enrollment of the study 9. Patients who have or had drug abuse or drug dependence 10. Patients who are pregnant or possibly pregnant 11. Patients who are judged to be innapropriate for the study by the physician |
|||
| Target sample size | 35 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | National Hospital Organization Kinki-Chuo Chest Medical Center | ||||||
| Division name | Department of Psychosomatic Internal Medicine | ||||||
| Zip code | |||||||
| Address | 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan | ||||||
| TEL | 072-252-3021 | ||||||
| ymatsuda@kch.hosp.go.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | National Hospital Organization Kinki-Chuo Chest Medical Center | ||||||
| Division name | Department of Psychosomatic Internal Medicine | ||||||
| Zip code | |||||||
| Address | 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan | ||||||
| TEL | 072-252-3021 | ||||||
| Homepage URL | |||||||
| ymatsuda@kch.hosp.go.jp | |||||||
| Sponsor | |
| Institute | Non-Profit Organization JORTC |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Center for Geriatrics and Gerontology |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017782 |